| # | Drug | Count |
|---|---|---|
| 0 | OCRELIZUMAB | 557 |
| 1 | FINGOLIMOD HCL | 277 |
| 2 | ERGOCALCIFEROL | 109 |
| 3 | NATALIZUMAB | 98 |
| 4 | RITUXIMAB | 88 |
| 5 | GABAPENTIN | 84 |
| 6 | BACLOFEN | 83 |
| 7 | DALFAMPRIDINE | 78 |
| 8 | DIMETHYL FUMARATE | 69 |
| 9 | ACETAMINOPHEN | 66 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | QUINAPRIL AND HYDROCHLOROTHIAZIDE | 1 | 0.0119 |
| 1 | OCRELIZUMAB | 557 | 0.0089 |
| 2 | NATALIZUMAB-SZTN | 2 | 0.0084 |
| 3 | FINGOLIMOD HYDROCHLORIDE | 35 | 0.0069 |
| 4 | FINGOLIMOD LAURYL SULFATE | 1 | 0.0046 |
| 5 | ERGOCALCIFEROL | 109 | 0.0037 |
| 6 | FINGOLIMOD HCL | 277 | 0.0032 |
| 7 | PRUCALOPRIDE SUCCINATE | 1 | 0.0029 |
| 8 | PAMABROM | 1 | 0.0027 |
| 9 | OCRELIZUMAB AND HYALURONIDASE | 1 | 0.0020 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 668 |
| 1 | Integrin Receptor Antagonist [EPC] | 117 |
| 2 | Provitamin D2 Compound [EPC] | 109 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 102 |
| 4 | Corticosteroid [EPC] | 91 |
| 5 | gamma-Aminobutyric Acid-ergic Agonist [EPC] | 83 |
| 6 | Potassium Channel Blocker [EPC] | 78 |
| 7 | Benzodiazepine [EPC] | 71 |
| 8 | Pyrimidine Synthesis Inhibitor [EPC] | 50 |
| 9 | Interferon beta [EPC] | 45 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Provitamin D2 Compound [EPC] | 109 | 0.0037 |
| 1 | CD19-directed Cytolytic Antibody [EPC] | 3 | 0.0035 |
| 2 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 45 | 0.0032 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 668 | 0.0021 |
| 4 | Guanylate Cyclase-C Agonist [EPC] | 4 | 0.0019 |
| 5 | CD4-directed Blocking Antibody [EPC] | 1 | 0.0019 |
| 6 | Integrin Receptor Antagonist [EPC] | 117 | 0.0013 |
| 7 | Adrenocorticotropic Hormone [EPC] | 1 | 0.0011 |
| 8 | Pyrimidine Synthesis Inhibitor [EPC] | 50 | 0.0011 |
| 9 | Potassium Channel Blocker [EPC] | 78 | 0.0011 |